These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 38989419)
21. Baseline Tumor Lipiodol Uptake after Transarterial Chemoembolization for Hepatocellular Carcinoma: Identification of a Threshold Value Predicting Tumor Recurrence. Matsui Y; Horikawa M; Jahangiri Noudeh Y; Kaufman JA; Kolbeck KJ; Farsad K Radiol Oncol; 2017 Dec; 51(4):393-400. PubMed ID: 29333117 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of Transarterial Chemoembolization Protocol with Drug-Eluting Beads in Combination with Lipiodol for Hepatocellular Carcinoma: A Single-Center Controlled Study. Dong X; Wang Y; Hao J; Chen L; Sun T; Zhang W; Sun B; Zhu L; Guo Y; Zheng C J Oncol; 2022; 2022():1090313. PubMed ID: 36568640 [TBL] [Abstract][Full Text] [Related]
23. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Kloeckner R; Otto G; Biesterfeld S; Oberholzer K; Dueber C; Pitton MB Cardiovasc Intervent Radiol; 2010 Jun; 33(3):532-40. PubMed ID: 19847482 [TBL] [Abstract][Full Text] [Related]
24. Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation. Yang Z; Zou R; Zheng Y; Qiu J; Shen J; Liao Y; Zhang Y; Wang C; Wang Y; Yuan Y; Li K; Zuo D; He W; Liu W; Li B; Yuan Y Eur Radiol; 2019 Nov; 29(11):5752-5762. PubMed ID: 30993438 [TBL] [Abstract][Full Text] [Related]
25. The Degree of Lipiodol Accumulation Can Be an Indicator of Successful Treatment for Unresectable Hepatocellular Carcinoma (HCC) Patients - in the Case of Transcatheter Arterial Chemoembolization (TACE) and External Beam Radiotherapy (EBRT). Yang P; Zeng ZC; Wang BL; Zhang JY; Fan J; Zhou J; Hu Y J Cancer; 2016; 7(11):1413-20. PubMed ID: 27471557 [TBL] [Abstract][Full Text] [Related]
26. Lipiodol combined with drug-eluting beads versus drug-eluting beads alone for transarterial chemoembolization of hepatocellular carcinoma: a multicenter study. Ji K; Shi Y; Liang Z; Zhang C; Jing L; Xu T; Cao S; Zhou G; Cao Y; Niu J; Zhu J; Ai J; Li Z; Chen F Acad Radiol; 2024 Jun; ():. PubMed ID: 38866689 [TBL] [Abstract][Full Text] [Related]
27. Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study. Gruber-Rouh T; Schmitt C; Naguib NNN; Nour-Eldin NA; Eichler K; Beeres M; Vogl TJ BMC Cancer; 2018 Feb; 18(1):188. PubMed ID: 29444653 [TBL] [Abstract][Full Text] [Related]
28. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study. Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of two different transarterial chemoembolization protocols using Lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial. Vogl TJ; Langenbach MC; Hammerstingl R; Albrecht MH; Chatterjee AR; Gruber-Rouh T Hepatol Int; 2021 Jun; 15(3):685-694. PubMed ID: 34043158 [TBL] [Abstract][Full Text] [Related]
30. Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients. Lee S; Jung J; Park JH; Kim SY; Choi J; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Park HH; Kim JH; Yoon SM BMC Cancer; 2022 Feb; 22(1):175. PubMed ID: 35172769 [TBL] [Abstract][Full Text] [Related]
31. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma. Liu YS; Ou MC; Tsai YS; Lin XZ; Wang CK; Tsai HM; Chuang MT Korean J Radiol; 2015; 16(1):125-32. PubMed ID: 25598680 [TBL] [Abstract][Full Text] [Related]
32. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial. Letzen BS; Malpani R; Miszczuk M; de Ruiter QMB; Petty CW; Rexha I; Nezami N; Laage-Gaupp F; Lin M; Schlachter TR; Chapiro J Clin Imaging; 2021 Oct; 78():194-200. PubMed ID: 34022765 [TBL] [Abstract][Full Text] [Related]
33. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). Ma W; Jia J; Wang S; Bai W; Yi J; Bai M; Quan Z; Yin Z; Fan D; Wang J; Han G Theranostics; 2014; 4(7):736-44. PubMed ID: 24883123 [TBL] [Abstract][Full Text] [Related]
34. C-arm Lipiodol CT in transcatheter arterial chemoembolization for small hepatocellular carcinoma. Li JJ; Zheng JS; Cui SC; Cui XW; Hu CX; Fang D; Ye LC World J Gastroenterol; 2015 Mar; 21(10):3035-40. PubMed ID: 25780303 [TBL] [Abstract][Full Text] [Related]
35. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma. Niu XK; He XF World J Gastroenterol; 2021 Jan; 27(2):189-207. PubMed ID: 33510559 [TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of transcatheter arterial chemoembolization with embospheres in treatment of hepatocellular carcinoma. Hao MZ; Lin HL; Chen QZ; Hu YB; Chen JB; Zheng JX; Zhou D; Zhang H J Dig Dis; 2017 Jan; 18(1):31-39. PubMed ID: 27987344 [TBL] [Abstract][Full Text] [Related]
37. The value of paradoxical uptake of hepatocellular carcinoma on the hepatobiliary phase of gadoxetic acid-enhanced liver magnetic resonance imaging for the prediction of lipiodol uptake after transcatheter arterial chemoembolization. Kim JW; Lee CH; Park YS; Seo TS; Song MG; Kim JH; Kim KA; Park CM Eur J Radiol; 2017 Apr; 89():169-176. PubMed ID: 28267535 [TBL] [Abstract][Full Text] [Related]
38. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447 [TBL] [Abstract][Full Text] [Related]
39. Survival and Outcome in Patients Receiving Drug-Eluting Beads Transarterial Chemoembolization for Large Hepatocellular Carcinoma (>5 cm). Mukund A; Bhardwaj K; Choudhury A; Sarin SK J Clin Exp Hepatol; 2021; 11(6):674-681. PubMed ID: 34866846 [TBL] [Abstract][Full Text] [Related]
40. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: exploring the influence of prior transarterial chemoembolization and additional transarterial chemoembolization on survival outcomes. Hien PN; Chun HJ; Oh JS; Kim SH; Choi BG J Gastrointest Oncol; 2024 Apr; 15(2):721-729. PubMed ID: 38756625 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]